Bayer to Present Results From Phase III FIDELIO-DKD Study with Finerenone in Patients with Chronic Kidney Disease and Type 2 Diabetes during Late-Breaker Session at the American Society of Nephrology’s Kidney Week 2020

WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer will present detailed results from the Phase III FIDELIO-DKD study assessing the use of the investigational drug finerenone on kidney and cardiovascular outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) during scientific sessions of the upcoming American Society of Nephrology’s (ASN) Kidney Week, October 22-25, 2020. Additional data evaluating use of finerenone will also be presented.

The FIDELIO-DKD study, which evaluated the efficacy and safety of finerenone versus placebo when added to standard of care in patients with CKD and T2D, is the first large contemporary positive outcomes study in patients with CKD and T2D with a primary composite endpoint exclusively consisting of kidney-specific outcomes. Bayer announced earlier this year that FIDELIO-DKD met its composite primary renal endpoint and its composite key secondary cardiovascular endpoint.

Full data from the FIDELIO-DKD study will be presented as part of the live-streamed, late-breaker

Read More

Utah Huntington’s Disease Society to hold virtual Team Hope Walk | Local News

The Utah chapter of the Huntington’s Disease Society of America will be hosting its annual Team Hope Walk with a twist this year.

Due to the COVID-19 pandemic the organization is transitioning into a virtual format, welcoming people to walk wherever they would prefer for the fundraising event on Oct. 17.

According to the HDSA website, Huntington’s disease is a fatal genetic disorder causing the breakdown of cells in the brain as well as the deterioration of a person’s physical and mental abilities. There are currently 41,000 symptomatic Americans with more than 200,000 at risk of inheriting the disease.

For Morgan Pratt, the Utah chapter president, Huntington’s disease is something she has been dealing with throughout her life. Pratt’s mother passed away due to complications from the disease and Pratt was then diagnosed with it about two years ago at the age of 23.

“We are on the cusp of

Read More

Dynacure to Present Disease Progression Model and Natural History Study Data at the 25th Annual Congress of the World Muscle Society (WMS25)

STRASBOURG, Pa. and PHILADELPHIA, Sept. 28, 2020 /PRNewswire/ — Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, announced today that the company will present two posters containing data on the natural history of Myotubular and Centronuclear Myopathies (CNM) at the 25th Annual Congress of the World Muscle Society (WMS25).  The WMS25 meeting is being held in a virtual format. 

Dynacure is developing DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 (DNM2), for the treatment of CNM.  DYN101 is currently being evaluated in a Phase 1/2 clinical study, ‘UNITE-CNM’ (DYN101-C101), at multiple clinical sites in Europe. 

Details of the poster presentations are listed below:

Poster Abstract: # LSP (late submitted poster) 6
Title: Hierarchical Bayesian model of disease progression in centronuclear myopathy allows to demonstrate treatment efficacy with a small sample size
Date: Thursday,

Read More